{
    "clinical_study": {
        "@rank": "151446", 
        "acronym": "SPRY", 
        "arm_group": [
            {
                "arm_group_label": "Progesterone 225 mg/day", 
                "arm_group_type": "Active Comparator", 
                "description": "Progesterone + Placebo"
            }, 
            {
                "arm_group_label": "Progesterone, 300 mg/ day", 
                "arm_group_type": "Active Comparator", 
                "description": "Progesterone + Placebo"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will be a Phase 3, randomized, three-cycle, double-blind, placebo-controlled,\n      parallel group, multiple-dose design.\n\n      The study design has four phases: Screening Period; Open-Label Estrogen-Priming Period\n      (Run-In Period); Blinded Treatment Period; and Follow-Up.  The Open Label Priming Period and\n      Blinded Treatment Period cover a total of three 28-day cycles. Clinical evaluations will be\n      performed at the following time points:\n\n      Screening Period:\n\n      \u2022 Screening Period (approximately 42 Days)\n\n      Open-Label Estrogen Priming Period (Run In Period):\n\n        -  Visit 1 Baseline (Cycle 1, Day 1)\n\n        -  Telephone Interview (Cycle 1, Day 28 [- 3 d to \u00b11d])\n\n      Blinded Treatment Period:\n\n        -  Visit 2 Randomization (Cycle 2, Day 12 [\u00b12d])\n\n        -  Visit 3 Interim (Cycle 3, Day 12 [\u00b12d])\n\n        -  Visit 4 End of treatment (Cycle 3, Day 24 [\u00b11d])\n\n      Follow-Up Period:\n\n        -  Visit 5 Follow-Up (Approximately 10 days after the last treatment)\n\n        -  Telephone Interview (Approximately 2-4 weeks after completion of progestin course)\n           (Only applies to subjects receiving an approved progestin therapy for  proliferative\n           endometrium, as determined by biopsy.)"
        }, 
        "brief_title": "A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea", 
        "condition": "Secondary Amenorrhea", 
        "condition_browse": {
            "mesh_term": [
                "Amenorrhea", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be female, premenopausal, 18 to 40 years of age (inclusive, at the time of\n             randomization)\n\n          -  Have secondary amenorrhea, defined as the absence of menstruation for at least 90\n             days prior to Visit 1 (Cycle 1, Day 1).\n\n          -  Have an intact uterus.\n\n          -  Be otherwise healthy, as judged by the Investigator physician, based on a medical\n             evaluation performed during the screening period prior to the initial dose of\n             Estrace\u00ae. The medical evaluation must include:\n\n               -  a normal or non-clinically significant physical examination, including vital\n                  signs (sitting blood pressure, heart rate, respiratory rate and temperature).\n                  Acceptable sitting systolic blood pressure is <140 mmHg and diastolic blood\n                  pressure is <90 mmHg at screening. A subject may be taking up to two\n                  antihypertensive medications.\n\n               -  a normal or non-clinically significant pelvic examination performed during\n                  screening.\n\n               -  a normal or non-clinically significant clinical breast examination performed\n                  during screening. An acceptable breast examination is defined as no masses,\n                  adenopathy, or other findings identified that are suspicious of malignancy.\n\n               -  a normal or non-clinically significant 12-lead ECG as determined by the\n                  Principal Investigator (PI) or medical Sub-Investigator.\n\n          -  Have a negative serum pregnancy test at Screening, and be willing to use an\n             acceptable form of non-hormonal birth control (e.g., barrier method with spermicide)\n             during the study. (The \"rhythm method,\" withdrawal, or an IUD are NOT acceptable\n             methods.)\n\n        Exclusionary:\n\n          -  Be postmenopausal.\n\n          -  Be diagnosed with primary amenorrhea.\n\n          -  Have had bilateral oophorectomy and/or hysterectomy.\n\n          -  Have a history of thrombosis of deep veins or arteries or a thromboembolic disorder.\n\n          -  Have a history of coronary artery or cerebrovascular disease (e.g., myocardial\n             infarction, stroke, TIA).\n\n          -  Have a history of liver or kidney dysfunction/disorder (e.g., hepatitis C or chronic\n             renal failure).\n\n          -  Have a history of gallbladder dysfunction/disorders (e.g., cholangitis,\n             cholecystitis), unless gallbladder has been removed.\n\n          -  Have a history of diabetes, thyroid disease or any other endocrine disease. (Subjects\n             with diet-controlled diabetes or controlled hypothyroid disease at screening are not\n             excluded.)\n\n          -  Have a history of undiagnosed vaginal bleeding.\n\n          -  Have any history of endometrial hyperplasia, uterine/endometrial, breast or ovarian\n             cancer.\n\n          -  Have any history of malignancy within the last 5 years, with the exception of basal\n             cell (excluded if within one year) or squamous cell (excluded if within one year)\n             carcinoma of the skin.\n\n          -  Have a history of any other cardiovascular, hepatic, renal, pulmonary, hematologic,\n             gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychological, or\n             musculoskeletal disease or disorder that is clinically significant in the opinion of\n             the Principal Investigator or medical Sub-Investigator.\n\n          -  Have used injectable or implantable estrogen, progestin/progesterone, testosterone or\n             androgens within the last 6 months prior to Visit 1 or plan to use them during the\n             study.\n\n          -  Have used any of the following hormonal products within the last 90 days prior to\n             Visit 1 or plan to use them during the study:\n\n               -  Vaginal nonsystemic hormonal products (rings, creams, gels) or vaginal systemic\n                  hormonal products (e.g., FemRing).\n\n               -  Transdermal estrogen alone or combination estrogen and progestin/progesterone\n                  products.\n\n               -  Oral hormonal birth control or oral estrogen and/or progestin/progesterone\n                  therapy.\n\n               -  Percutaneous estrogen lotions/gels.\n\n          -  Have used oral, topical, vaginal, or patch testosterone or androgen therapy within\n             the last 8 weeks (56 days) prior to Visit 1 or plan to use them during the study.\n\n          -  Have used injectable corticosteroids within the last 42 days prior to Visit 1 or plan\n             to use them during the study.\n\n          -  Have used an IUD (either hormonal or non-hormonal) within the previous 90 days prior\n             to Visit 1 or plan to use one during the study.\n\n          -  Have used, within 28 days prior to the initial dose of Estrace\u00ae at Baseline Visit 1,\n             or plan to use during the study, any prescription or over-the-counter (OTC)\n             medications (including herbal products, such as St. John's Wort) that would be\n             expected to alter progesterone activity. (For additional details, see Concomitant and\n             Prohibited Medications, Section 4.3.\n\n          -  Have participated in another clinical trial within 30 days prior to screening, have\n             received an investigational drug within the 90 days prior to the initial dose of\n             Estrace\u00ae, or be likely to participate in a clinical trial or receive another\n             investigational medication during the study.\n\n          -  Have contraindication to any planned study assessments (e.g., endometrial biopsy)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019589", 
            "org_study_id": "TXP13-01"
        }, 
        "intervention": {
            "arm_group_label": [
                "Progesterone 225 mg/day", 
                "Progesterone, 300 mg/ day"
            ], 
            "intervention_name": "Progesterone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Progesterone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Secondary Amenorrhea", 
            "SPRY Trial"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "location": [
            {
                "contact": {
                    "email": "mari@precisiontrials.com", 
                    "last_name": "Mari Alexander", 
                    "phone": "602-931-4507", 
                    "phone_ext": "221"
                }, 
                "facility": {
                    "address": {
                        "city": "Chandler", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85224"
                    }, 
                    "name": "Precision Trials/New Horizons Women's Care"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mari@precisiontrials.com", 
                    "last_name": "Mari Alexander", 
                    "phone": "602-931-4507", 
                    "phone_ext": "221"
                }, 
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85032"
                    }, 
                    "name": "Precision Clinical Trials/Arizona Wellness Center for Women"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "BPollock@visionstucson.com", 
                    "last_name": "Brenda Pollock", 
                    "phone": "520-546-4700"
                }, 
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85712"
                    }, 
                    "name": "Visions Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "porterj@cfhc.org", 
                    "last_name": "Julia Porter", 
                    "phone": "800-300-5767", 
                    "phone_ext": "2205"
                }, 
                "facility": {
                    "address": {
                        "city": "Berkley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94710"
                    }, 
                    "name": "California Family Health Council"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Research@cfhc.org", 
                    "last_name": "Anna Garcia", 
                    "phone": "800-521-5211"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90010"
                    }, 
                    "name": "California Family Health Council"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "RPierce@clinicalrc.com", 
                    "last_name": "Rachel Pierce", 
                    "phone": "203-878-9713"
                }, 
                "facility": {
                    "address": {
                        "city": "Milford", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06460"
                    }, 
                    "name": "Clinical Research Consulting"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bcharette@encoredocs.com", 
                    "last_name": "Brandie Charette", 
                    "phone": "352-341-2100"
                }, 
                "facility": {
                    "address": {
                        "city": "Crystal River", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34429"
                    }, 
                    "name": "Nature Coast Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "abarron@cctllc.net", 
                    "last_name": "Andrea Barron", 
                    "phone": "561-478-3177"
                }, 
                "facility": {
                    "address": {
                        "city": "West Palm Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33409"
                    }, 
                    "name": "Comprehensive Clinical Trials, LLC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bryan@cypressmrc.com", 
                    "last_name": "Bryan Baker", 
                    "phone": "316-425-6333"
                }, 
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67226"
                    }, 
                    "name": "Cypress Medical Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "leldredwc@neb.rr.com", 
                    "last_name": "Laura Eldred", 
                    "phone": "402-441-0025"
                }, 
                "facility": {
                    "address": {
                        "city": "Lincoln", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68510"
                    }, 
                    "name": "Women's Clinic of Lincoln, P.C."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mpender@lawrenceobgyn.com", 
                    "last_name": "Michele Pender", 
                    "phone": "609-803-2378"
                }, 
                "facility": {
                    "address": {
                        "city": "Lawrenceville", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08648"
                    }, 
                    "name": "Lawrence OB-Gyn Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mhurst@prohealthcare.com", 
                    "last_name": "Maureen Hurst", 
                    "phone": "631-656-4060"
                }, 
                "facility": {
                    "address": {
                        "city": "Port Jefferson", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11777"
                    }, 
                    "name": "Suffolk OBGYN"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lcathey@wakeresearch.com", 
                    "last_name": "Laura Cathey", 
                    "phone": "919-781-2514"
                }, 
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27615"
                    }, 
                    "name": "Wake Research Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "abutler@lyndhurstgyn.com", 
                    "last_name": "Amy Butler", 
                    "phone": "336-397-3716"
                }, 
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27103"
                    }, 
                    "name": "Lyndhurst Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Tiffany.Rupert@uc.edu", 
                    "last_name": "Tiffany Rupert", 
                    "phone": "336-397-3716"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229"
                    }, 
                    "name": "University of Cincinnati Physicians Company"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "svanmeeveren@hwcwrc.com", 
                    "last_name": "Stephanie VanMeeveren", 
                    "phone": "937-771-5100"
                }, 
                "facility": {
                    "address": {
                        "city": "Englewood", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45322"
                    }, 
                    "name": "HWC Women's Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29201"
                    }, 
                    "name": "Vista Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ychester@chattmedresearch.com", 
                    "last_name": "Yvonne Chester", 
                    "phone": "423-648-7796"
                }, 
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37404"
                    }, 
                    "name": "Chattanooga Medical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "andylongoria@yahoo.com", 
                    "last_name": "Andy Longoria", 
                    "phone": "972-298-4981"
                }, 
                "facility": {
                    "address": {
                        "city": "Desoto", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75115"
                    }, 
                    "name": "Methodist Charlton Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lori.wink@hcahealthcare.com", 
                    "last_name": "Lori Wink", 
                    "phone": "713-790-8500"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77054"
                    }, 
                    "name": "The Woman's Hospital of Texas Clinical Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "genebach@proslc.com", 
                    "last_name": "Peggy Genebach", 
                    "phone": "801-352-9228"
                }, 
                "facility": {
                    "address": {
                        "city": "Sandy", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84070"
                    }, 
                    "name": "PRO/Salt Lake Women's Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tcrrusch@cox.net", 
                    "last_name": "April Rusch", 
                    "phone": "757-471-3375", 
                    "phone_ext": "111"
                }, 
                "facility": {
                    "address": {
                        "city": "Virginia Beach", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23456"
                    }, 
                    "name": "Tidewater Clinical Research"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding After Administration of TX-12-002-HR in Estrogen-Primed Women With Secondary Amenorrhea", 
        "overall_contact": {
            "email": "sebastian.mirkin@therapeuticsmd.com", 
            "last_name": "Sebastian Mirkin, MD", 
            "phone": "561-961-1900", 
            "phone_ext": "1952"
        }, 
        "overall_contact_backup": {
            "email": "michelle.beelitz@therapeuticsmd.com", 
            "last_name": "Michelle Beelitz, BS", 
            "phone": "561-961-1900", 
            "phone_ext": "1928"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "\u2022 The proportion of subjects at Cycle 3 Day 24 \u00b1 1 day on active treatment compared to placebo with complete secretory activity on endometrial biopsy.", 
            "safety_issue": "Yes", 
            "time_frame": "3 Cycles"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019589"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "\u2022 The proportion of subjects at Cycle 3 Day 24 \u00b1 1 day on active treatment compared to placebo with total secretory activity (defined as the aggregate of partial and complete secretory activity) on endometrial biopsy.", 
            "safety_issue": "Yes", 
            "time_frame": "3 cycles"
        }, 
        "source": "TherapeuticsMD", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TherapeuticsMD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}